Pfizer’s Prevenar 13® Receives Approval For Use in Infants and Children in China

NEW YORK–(BUSINESS WIRE)– Pfizer China announced today that it has received approval from the
Chinese Food and Drug Administration (CFDA) to market its pneumococcal
13-valent conjugate vaccine, Prevenar 13®, in China for active
immunization for the prevention of invasive diseases (including
bacteremic pneumonia, meningitis, septicemia, and bacteremia) caused by
Streptococcus pneumoniae (S. Pneumoniae) serotypes 1, 3, 4, 5, 6A, 6B,
7F, 9V, 14, 18C, 19A, 19F, and 23F in infants and children aged 6 weeks
to 15 months. S. pneumoniae is the most common cause of invasive disease
as well as pneumonia and upper respiratory tract infections.

Pneumococcal disease is a leading cause of vaccine-preventable deaths
globally in children under five years old¹. In China alone,
approximately 30 thousand children in this age group die due to
pneumococcal diseases every year².

« We applaud the efforts of CFDA and other relevant Chinese government
agencies to bring new medicines and vaccines to the Chinese healthcare
system,” said Dr. Xiaobin Wu, President of Pfizer China. “Pfizer is
committed to working closely with the CFDA in these efforts, and also
looks forward to partnering with the Chinese government to help improve
the lives of patients and people of all ages in China.”

In China, the recommended Prevenar 13® immunization series is a primary
series administered at 2, 4 and 6 months of age with a fourth (booster)
dose administered at approximately 12~15 months of age.

About Streptococcus Pneumoniae

Pneumococcus (also known as Streptococcus pneumoniae) is widely
colonized in the human nasopharynx, with a carrier rate of 27% – 85%;
infants and young children are the main carrier and transmission group³.
Pneumococcus can be spread through respiratory droplets. Vaccination in
children is critical as their immune systems are still developing during
the first years of life, leaving them more susceptible to infectious
diseases⁴. Serious sequelae such as deafness, developmental
delay and even death can be associated with invasive pneumococcal disease⁵.
Due to the increasingly serious problem of multi-drug resistance to
pneumococcus, the clinical treatment of pneumococcus related diseases
has also become more difficult⁶.

Pneumococcal disease is a leading cause of vaccine-preventable deaths in
children under 5 years old globally and in China⁷. In view of
the large public health problem caused by pneumococcal disease, the
World Health Organization (WHO) has prioritized vaccination against this
disease worldwide⁸.

About Prevenar 13^®

Prevenar 13® is the most widely used pneumococcal conjugate vaccine in
the world, and is included in the pediatric National Immunization
Programs of numerous countries in the Asia Pacific region such as
Australia, Hong Kong, Japan, and Taiwan^9,10 Prevenar 13® will
only protect against Streptococcus pneumoniae serotypes included in the
vaccine, and will not protect against serotypes not present in the
vaccine or other microorganisms that cause invasive disease, pneumonia,
or otitis media.

Prevnar 13^® is the trade name in the United States, Canada,
and Taiwan.

U.S. IMPORTANT SAFETY INFORMATION

• Prevnar 13^® should not be given to anyone with a history of
  severe allergic reaction to any component of Prevnar 13^® or
  any diphtheria toxoid–containing vaccine
• Children and adults with weakened immune systems (eg, HIV infection,
  leukemia) may have a reduced immune response
• A temporary pause of breathing following vaccination has been observed
  in some infants born prematurely
• The most commonly reported serious adverse events in infants and
  toddlers were bronchiolitis (an infection of the lungs) (0.9%),
  gastroenteritis (inflammation of the stomach and small intestine)
  (0.9%), and pneumonia (0.9%)
• In children 6 weeks through 17 years, the most common side effects
  were tenderness, redness, or swelling at the injection site,
  irritability, decreased appetite, decreased or increased sleep, and
  fever
• Only a healthcare provider can decide if Prevnar 13^® is
  right for an individual

For the full prescribing information for Prevnar 13^®, please
click here http://www.pfizer.com/products/product-detail/prevnar_13.

Pfizer Inc.: Working together for a healthier world^TM

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com
and follow us on Twitter at @Pfizer
and @PfizerNews,
LinkedIn,
YouTube
and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this release
is as of November 2, 2016. Pfizer assumes no obligation to update
forward-looking statements contained in this release as the result of
new information or future events or developments.

This release contains forward-looking information about Prevnar
13/Prevenar 13, including its potential benefits, that involves
substantial risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements.
Risks and uncertainties include, among other things, uncertainties
regarding the commercial success of Prevnar 13/Prevenar 13; the
uncertainties inherent in research and development, including the
ability to meet anticipated clinical trial completion dates and
regulatory submission dates, as well as the possibility of unfavorable
clinical trial results; whether and when any applications that are
pending or that may be filed may be approved by regulatory authorities,
which will depend on the assessment by such regulatory authorities of
the benefit-risk profile suggested by the totality of the efficacy and
safety information submitted; decisions by regulatory authorities
regarding labeling and other matters that could affect the availability
or commercial potential of Prevnar 13/Prevenar 13; and competitive
developments.-5-

A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2015 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results,” as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at www.sec.gov
and www.pfizer.com.

# # # # #

¹ WHO Centers for Disease Control and Prevention.
Pneumococcal disease. In: Atkinson W, Wolfe S, Hamborsky J, eds.
Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed.
Washington, DC: Public Health Foundation; 2011:233-248. Available at: http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.
Accessed January 28, 2015.

² O’Brien KL, et al. Burden of disease caused by
Streptococcus pneumoniae in children younger than 5 years: global
estimates. Lancet. 2009; 374(9693): 893-902.

³ Lynch JP 3rd,et al. Semin Respir Crit Care Med. 2009;30(2):
189-209.

⁴ Offit P, Quarles J, Gerber M, et al. Addressing Parents’
Concerns: Do Multiple Vaccines Overwhelm or Weaken the Infant’s Immune
System? Pediatrics. 2002;109:124-129.

⁵ Pneumococcal Disease – Symptoms and Complications, Centers
for Disease Control and Prevention. http://www.cdc.gov/pneumococcal/about/symptoms-complications.html

⁶ Chin J. Epidemiol. November 2012, Vol 33, No.
11.

⁷ Levine OS, Liu G, Garman RL, Dowell SF, Yu S, Yang YH.
Haemophilus influenzae type b and Streptococcus pneumoniae as causes of
pneumonia among children in Beijing, China. Emerg Infect Dis. 2000.
6(2): 165-70

⁸ WHO. Meeting of the immunization Strategic Advisory Group
of Experts, November 2007 –conclusions and Recommendations. Wkly
Epidemiol Rec, 2008;83:1-16.

⁹ GlaxoSmithKline. GSK’s Synflorix™ receives CHMP positive
opinion for major label extension. July 27, 2015. http://www.gsk.com/en-gb/media/press-releases/2015/gsk-s-synflorix-receives-chmp-positive-opinion-for-major-label-extension/.
Accessed July 7, 2016.

¹⁰ Data on file. Pfizer Inc, New York, NY. [Total Prevenar
13V Doses Through May 2016]

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161102005728/en/